Clinical Trials Logo

Adult Erythroleukemia (M6a) clinical trials

View clinical trials related to Adult Erythroleukemia (M6a).

Filter by:

NCT ID: NCT01839240 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

Start date: June 6, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of azacitidine when given together with cytarabine and mitoxantrone hydrochloride in treating patients with high-risk acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, cytarabine, and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may also help cytarabine and mitoxantrone hydrochloride work better by making the cancer cells more sensitive to the drugs

NCT ID: NCT01835288 Withdrawn - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: May 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well arsenic trioxide works in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

NCT ID: NCT01831232 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Start date: May 2013
Phase: N/A
Study type: Interventional

This clinical trial studies idarubicin, cytarabine, and pravastatin sodium in treating patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving idarubicin and cytarabine together with pravastatin sodium may kill more cancer cells.

NCT ID: NCT01822015 Completed - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Start date: March 15, 2013
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies sirolimus, idarubicin, and cytarabine in treating patients with newly diagnosed acute myeloid leukemia. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving sirolimus together with idarubicin and cytarabine may kill more cancer cells.

NCT ID: NCT01820624 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: April 30, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of tretinoin when given together with lithium carbonate in treating patients with relapsed or refractory acute myeloid leukemia. Lithium carbonate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tretinoin may help [type of cancer] cells become more like normal cells, and to grow and spread more slowly. Giving lithium carbonate together with tretinoin may kill more cancer cells

NCT ID: NCT01801046 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

Start date: March 6, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia. Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect)

NCT ID: NCT01607645 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The goals of this study are to learn about the effectiveness, the side-effects, if waiting to give the idarubicin and cytarabine may change the side effects or effectiveness, and to identify factors to predict for responses to this therapy. The trial will examine combination of three chemotherapy drugs. These drugs are decitabine, idarubicin, and cytarabine.

NCT ID: NCT01555268 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Start date: October 31, 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of trebananib when given together with or without low-dose cytarabine in treating patients with acute myeloid leukemia (AML). Trebananib may stop the growth of AML by blocking blood flow to the cancer. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving trebananib together with cytarabine may be an effective treatment for patients with AML.

NCT ID: NCT01550185 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

Start date: May 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out the highest safe dose and examine the side effects and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML) treated with chemotherapy that have not responded to previous therapy or have suffered a relapse

NCT ID: NCT01521936 Terminated - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This partially randomized phase II trial studies the side effects and best way to give and best dose of cholecalciferol in treating patients with acute myeloid leukemia (AML) undergoing intensive induction chemotherapy. Cholecalciferol may help improve the outcome of patients with AML undergoing intensive chemotherapy